Invuity (IVTY) and FRESENIUS SE &/S (FSNUY) Head to Head Comparison
FRESENIUS SE &/S (NASDAQ: IVTY) and Invuity (NASDAQ:IVTY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.
FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 0.8%. Invuity does not pay a dividend.
This table compares FRESENIUS SE &/S and Invuity’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|FRESENIUS SE &/S||5.37%||8.76%||3.52%|
Valuation & Earnings
This table compares FRESENIUS SE &/S and Invuity’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|FRESENIUS SE &/S||$38.28 billion||1.07||$2.05 billion||N/A||N/A|
|Invuity||$39.62 million||4.47||-$39.91 million||($2.20)||-3.34|
FRESENIUS SE &/S has higher revenue and earnings than Invuity.
Volatility & Risk
FRESENIUS SE &/S has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Invuity has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500.
This is a summary of current ratings and target prices for FRESENIUS SE &/S and Invuity, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|FRESENIUS SE &/S||1||0||0||0||1.00|
Invuity has a consensus target price of $7.67, suggesting a potential upside of 4.31%. Given Invuity’s stronger consensus rating and higher possible upside, analysts clearly believe Invuity is more favorable than FRESENIUS SE &/S.
Insider and Institutional Ownership
0.1% of FRESENIUS SE &/S shares are owned by institutional investors. Comparatively, 60.0% of Invuity shares are owned by institutional investors. 8.4% of Invuity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
FRESENIUS SE &/S beats Invuity on 7 of the 13 factors compared between the two stocks.
About FRESENIUS SE &/S
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and reusable illuminated surgical devices, which provide surgeons with illumination and direct visualization of surgical cavities. It offers various illuminated surgical devices, including Eikon LT illuminated retractor system for breast/oncoplastic/gynecology/EP/plastic/endocrine surgeries; Eiberg illuminated retractor systems for orthopedic surgeries; PhotonBlade, a recision illuminator for breast/plastics/EP/orthopedics surgeries; PhotonSaber Y, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general/gynecology/plastic surgeries; and PhotonSaber F, a handheld illuminator for spine/orthopedic/neurosurgery surgeries. The company also provides Breiten illuminated retractor systems for spine/orthopedic surgeries; Photonguide XT system, a drop-in intracavity illuminator for spine surgeries; Eika illuminated retractor systems for endocrine/spine/orthopedic surgeries; and PhotonVue, a system used in conjunction with IC Indocyanine for identifying and verifying blood flow in tissue, as well as is used in breast/plastic/colorectal surgeries. It sells its devices through direct sales representatives and independent sales agents; and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. The company was formerly known as Spotlight Surgical, Inc. and changed its name to Invuity, Inc. in 2007. Invuity, Inc. was incorporated in 2004 and is based in San Francisco, California.
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.